{
    "organizations": [],
    "uuid": "bfa4c454d2f32f9aea8eaca20397664d46bf0f9c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL5N1SS0QV",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncodesign Announces Interim Results Of Clinical Study With First Radiotracer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - ONCODESIGN SA:\n* ANNOUNCED ON FRIDAY PUBLICATION OF ABSTRACT WITH INTERIM RESULTS OF FIRST 12 PATIENTS PARTICIPATING IN CLINICAL STUDY WITH ITS FIRST RADIOTRACER\n* IN FIRST STAGE OF STUDY, 8 PATIENTS WITH EGFR MUTATIONS RECEIVED INJECTION OF RADIOTRACER\n* RESULTS SHOWED THAT RADIOTRACER DID REACH AND BIND TO ITS TARGET, WHETHER A PRIMARY OR METASTATIC TUMOR\n* SIGNAL REDUCTION AFTER ONE WEEK’S TREATMENT CONFIRMED THE PRESENCE OF THE THERAPEUTIC MOLECULE WITHIN THE TUMOR\n* IN TWO PATIENTS, THE RADIOTRACER ALSO ALERTED THE ONCOLOGIST TO PRESENCE OF BRAIN METASTASES, WHICH HAD GONE UNNOTICED UNTIL THEN\n* RESULTS PRESENTED AT ASCO (AMERICAN SOCIETY OF CLINICAL ONCOLOGY) ALSO INCLUDE FIRST 4 PATIENTS RECRUITED IN STUDY’S SECOND STAGE\n* THESE INITIAL RESULTS IN PATIENTS WITH NO EGFR MUTATION VALIDATE SPECIFICITY OF RADIOTRACER\nSource text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-21T14:28:00.000+03:00",
    "crawled": "2018-05-22T19:28:17.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "oncodesign",
        "sa",
        "announced",
        "friday",
        "publication",
        "abstract",
        "interim",
        "result",
        "first",
        "patient",
        "participating",
        "clinical",
        "study",
        "first",
        "radiotracer",
        "first",
        "stage",
        "study",
        "patient",
        "egfr",
        "mutation",
        "received",
        "injection",
        "radiotracer",
        "result",
        "showed",
        "radiotracer",
        "reach",
        "bind",
        "target",
        "whether",
        "primary",
        "metastatic",
        "tumor",
        "signal",
        "reduction",
        "one",
        "week",
        "treatment",
        "confirmed",
        "presence",
        "therapeutic",
        "molecule",
        "within",
        "tumor",
        "two",
        "patient",
        "radiotracer",
        "also",
        "alerted",
        "oncologist",
        "presence",
        "brain",
        "metastasis",
        "gone",
        "unnoticed",
        "result",
        "presented",
        "asco",
        "american",
        "society",
        "clinical",
        "oncology",
        "also",
        "include",
        "first",
        "patient",
        "recruited",
        "study",
        "second",
        "stage",
        "initial",
        "result",
        "patient",
        "egfr",
        "mutation",
        "validate",
        "specificity",
        "radiotracer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}